Mark Cuban on Why AI Could Turn Solo Founders Into Trillionaires

在最近的一期播客节目中，主持人埃里克（Eric）和朱莉（Julie）迎来了马克·库班（Mark Cuban），共同探讨医疗健康市场的现状、Cost Plus Drugs的崛起，以及人工智能的变革潜力。 马克·库班开场指出，医疗健康市场严重破产，缺乏基本的竞争动态和价格发现机制。他指出，像联合健康（UnitedHealth）这样的垂直整合在位企业，通过数千家子公司和庞大的内部公司间转让，不断通过提高保费和免赔额来挤压雇主和患者，同时暗中强迫他们与全资子公司建立合作关系。 库班详细阐述了Cost Plus Drugs自2022年1月推出时的111种仿制药，到目前提供大约4,000个SKU的发展历程。他解释了该业务的多管齐下扩张： - **邮购与本地取货：** 通过Team Cuban Card，患者可以通过17,000家独立药房在本地获取药物。虽然该公司支付12美元的调剂费以支持独立药房，但他们在特种仿制药、生物仿制药以及胰岛素等冷链运输物品上仍然要便宜得多。 - **达拉斯制造与机器人舱：** 库班的联合创始人亚历克斯·奥什马扬斯基博士（Dr. Alex Oshmayansky）利用人工智能和机器人技术，将一个大型制造厂缩小到5,000平方英尺，使他们能够生产医院急需的短缺药品，并每四个小时迅速转换一次生产线。他们还制造了价值2000万美元的便携式“药舱”——这种拖挂车大小的制造厂可以部署到研究型医院用于治疗，或者由政府运送以应对生态、天气或军事灾难。 - **Cost Plus市场：** 以低加价向诊所和医院出售无菌注射剂和其他医院采购的产品。 - **直接签约：** 试图通过向医院首席执行官和首席财务官提供直接合同，来绕过传统的行政管理者（ASO）。这些合同消除了事先授权和拒绝理赔，同时建立了透明的开源模板，任何雇主都可以用它来谈判更好的条款。 朱莉指出，这种去中介化符合医疗计划更广泛的“大置换周期”，因为自保型雇主面临着大规模的年复一年保费上涨。库班强调，解决医疗成本的最终方案是让雇主在签署庞大且复杂的合同（通常超过1,000页）*之前*，通过人工智能代理运行这些合同，以揭露隐藏的陷阱和价格差价。 在讨论人工智能时，库班认为，虽然人工智能在运营和临床方面很有用，但其最大的直接威力在于合同分析和消费者教育。他经常使用人工智能代理和前沿模型来抓取公共记录，分析复杂的PBM（药品福利管理机构）和ASO合同，并找出企业被过度收费的地方。他强调，如果代表60%参加自保计划的美国人的雇主只是将他们的合同通过人工智能运行，大型保险公司和PBM将会崩溃。 展望未来，库班设想了一个被彻底颠覆、负担得起的医疗健康未来，这是由通用数据、通过他们的药舱实现的仿制药本土化制造，以及由先进人工智能模型驱动的个性化医疗所促成的。他建议年轻的企业家和企业高管团队不要再害怕人工智能，学会如何使用代理，并利用技术来提出艰难的问题。最后，在政策改革方面，库班主张将所有纳税人资助的合同公开且不加删节，允许更便宜的药价计入免赔额，公开非营利医院的账目，并创建一个由政府担保的个人医疗储蓄和贷款系统，最终消除对传统保险公司的需求。

In a recent podcast episode, hosts Eric and Julie welcomed Mark Cuban to discuss the current state of the healthcare market, the rise of Cost Plus Drugs, and the transformative potential of artificial intelligence. Mark Cuban opened by highlighting that the healthcare market is severely broken and lacks basic competitive dynamics and price discovery. He pointed out that vertically integrated incumbents like UnitedHealth, through thousands of subsidiaries and massive intercompany transfers, continuously squeeze employers and patients by raising premiums and deductibles while secretly forcing them into relationships with wholly-owned subsidiaries. Cuban detailed the evolution of Cost Plus Drugs since its launch in January 2022 with 111 generic medications to its current offering of roughly 4,000 SKUs. He explained the multi-pronged expansion of the business: - **Mail-Order and Local Pickup:** Through the Team Cuban Card, patients can access medications locally via 17,000 independent pharmacies. While the company pays a $12 fill fee to support independent pharmacies, they remain significantly cheaper on specialty generics, biosimilars, and cold-shipped items like insulin. - **Dallas Manufacturing and Robotic Pods:** Cuban’s co-founder, Dr. Alex Oshmayansky, utilized AI and robotics to shrink a large-scale manufacturing plant into 5,000 square feet, allowing them to produce essential hospital short-supply drugs and rapidly switch production lines every four hours. They also created $20 million portable "pods"—tractor-trailer-sized manufacturing plants that can be deployed to research hospitals for therapies or shipped by the government for ecological, weather, or military disasters. - **Cost Plus Marketplace:** Selling sterile injectables and other hospital-sourced products at a low markup to clinics and hospitals. - **Direct Contracting:** Attempting to bypass traditional administrators (ASOs) by offering direct contracts to hospital CEOs and CFOs. These contracts eliminate prior authorizations and denials while establishing transparent, open-source templates that any employer can use to negotiate better terms. Julie noted that this disintermediation aligns with a broader "great replacement cycle" for health plans, as self-insured employers face massive year-over-year premium hikes. Cuban stressed that the ultimate solution to healthcare costs is for employers to run their massive, complex contracts (often over 1,000 pages) through AI agents *before* signing them to expose hidden traps and pricing spreads. When discussing AI, Cuban argued that while AI is useful operationally and clinically, its greatest immediate power lies in contractual analysis and consumer education. He routinely uses AI agents and frontier models to scrape public records, analyze complex PBM and ASO contracts, and find where enterprises are being overcharged. He emphasized that if employers representing the 60% of Americans on self-insured plans simply ran their contracts through AI, the big carriers and PBMs would collapse. Looking ahead, Cuban envisions a future of completely disrupted, affordable healthcare enabled by universal data, onshored generic manufacturing through their pods, and personalized medicine driven by advanced AI models. He advised young entrepreneurs and enterprise C-suites alike to stop fearing AI, learn how to use agents, and leverage technology to ask the hard questions. Finally, for policy reform, Cuban advocated for making all taxpayer-funded contracts public without redactions, allowing cheaper drug prices to count toward deductibles, opening non-profit hospital ledgers, and creating a government-guaranteed personal healthcare savings and loan system that ultimately removes the need for traditional insurance carriers.